News

Brief news reports on Tuberculosis

Vaccine targeting latent TB enters clinical testing

COPENHAGEN, DENMARK/ROCKVILLE, MD, USA, December 1, 2011 – Statens Serum Institut and Aeras today announce the initiation of the first Phase I clinical trial of a new candidate TB vaccine designed to protect people latently infected with TB from developing active TB disease.  The trial is being conducted by the South African Tuberculosis Vaccine Initiative (SATVI) at its field site in Worcester, in the Western Cape province of South Africa. Dr. Hassan Mahomed is the principal investigator.

Read More →

WTO General Council extends deadline for TRIPS health amendment

The first and only amendment to the 1994 World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) was agreed with much aplomb at the Hong Kong ministerial in 2005. But getting countries to ratify the amendment has proven more difficult.

Read More →

New tuberculosis research movement needed

In this week's PLoS Medicine, Christian Lienhardt from the WHO in Geneva, Switzerland and colleagues announce that the Stop TB Partnership and the WHO Stop TB Department have launched the TB Research Movement.

Read More →

Peru admits 32.477 TB cases as part of the campaign to combat the disease

Peru has 37% of all multi-resistant tuberculosis cases in the Americas and one in four patients of the disease abandon medication in a mild stage of the disease according to the World Health Organization.

Read More →

The influence of TB treatment on efavirenz clearance in patients co-infected with HIV and TB

Concomitant rifampicin-containing tuberculosis treatment reduced apparent efavirenz clearance with a corresponding increase in efavirenz exposure.

Read More →

South Africa: MEC Dhlomo to call on everyone to work towards 'Getting to Zero' during this World Aids Day

The MEC for Health Dr Sibongiseni Dhlomo invites the media to the World AIDS Day commemoration where he would be outlining government's Provincial Strategic Plan 2012 - 2016, highlight issues around disability and HIV as well as launch the Men's Forum in Amajuba.

Read More →

‘Legal’ push for illegal TB kits in India

After Chinese mobile phones and toys, it’s the serological test kits from the Dragon that are flooding the Indian market. But more importantly, they are being commercially used rampantly by private medical practitioners to diagnose tuberculosis (TB) in violation of WHO guidelines.

Read More →

Researchers validate preclinical effectiveness of TB drug target that could shorten treatment time

Menlo Park, Calif. — November 29, 2011 — In research at SRI International, scientists evaluating new drug targets against tuberculosis (TB) recently validated the preclinical effectiveness of a target that could rapidly eliminate infections and potentially shorten treatment time. The new drug target is a protein called DNA gyrase B, found in bacteria that cause TB infections.

Read More →

Tuberculosis drug target’s structure to point to new therapies

Scientists at the John Innes Centre led by Dr Stephen Bornemann and Dr Dave Lawson have worked out the structure of a class of enzyme that has been genetically validated as a new drug target in Mycobacterium tuberculosis, a pathogenic bacterium which is responsible for 2 million tuberculosis deaths worldwide each year. The scientists have been awarded over £500,000 by the Biotechnology and Biological Sciences Research Council (BBSRC) to work out how this enzyme works and is regulated, which will help in the development of new therapies against tuberculosis.

Read More →

GDF invites applications for twenty-sixth round of grants

28 November 2011 - Geneva - The Stop TB Partnership's Global Drug Facility (GDF) is inviting applications for its twenty-sixth round of grants.

Read More →

Page 575 of 598 · Total posts: 10

←First 574 575 576 Last→